Surfacen® inhibited Th2 inflammation by lowering levels of IL‐5 and IL‐13 and increasing INF‐γ in bronchoalveolar lavage, decrease of serum specific IgE, increase of IgG2a antibody, suggesting potential anti‐allergy effects towards Th1‐immune response (Blanco et al., 2022). The gene discussed is IL13; the disease is Allergy.